JP2015506352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506352A5 JP2015506352A5 JP2014549212A JP2014549212A JP2015506352A5 JP 2015506352 A5 JP2015506352 A5 JP 2015506352A5 JP 2014549212 A JP2014549212 A JP 2014549212A JP 2014549212 A JP2014549212 A JP 2014549212A JP 2015506352 A5 JP2015506352 A5 JP 2015506352A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- treatment
- antagonist
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000005557 antagonist Substances 0.000 claims 6
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000017066 negative regulation of growth Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/374,369 US8946159B2 (en) | 2011-12-22 | 2011-12-22 | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
| US13/374,369 | 2011-12-22 | ||
| PCT/US2012/070399 WO2013096335A1 (en) | 2011-12-22 | 2012-12-18 | Administration of an antagonist of alpha 5 beta 1 for anti-antiogenesis and cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506352A JP2015506352A (ja) | 2015-03-02 |
| JP2015506352A5 true JP2015506352A5 (enExample) | 2016-05-19 |
| JP6224615B2 JP6224615B2 (ja) | 2017-11-01 |
Family
ID=48655153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014549212A Active JP6224615B2 (ja) | 2011-12-22 | 2012-12-18 | 抗血管新生およびがん処置のためのα５β１のアンタゴニストの投与 |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US8946159B2 (enExample) |
| EP (2) | EP2793924B1 (enExample) |
| JP (1) | JP6224615B2 (enExample) |
| CN (1) | CN104159596B (enExample) |
| WO (1) | WO2013096335A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110319335A1 (en) | 2010-06-23 | 2011-12-29 | Xiaodong Feng | Combined administration of integrin receptor antagonists for anti-angiogenic therapy |
| US8946159B2 (en) * | 2011-12-22 | 2015-02-03 | California Northstate College Of Pharmacy, Llc | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
| TWI579299B (zh) * | 2014-08-22 | 2017-04-21 | 國立成功大學 | 去整合蛋白變異體及其醫藥用途 |
| US11597727B2 (en) | 2018-03-13 | 2023-03-07 | The Regents Of The University Of California | Inhibitors of integrin alpha 2 beta 1 and methods of use |
| EP4142707A4 (en) | 2020-05-01 | 2024-09-18 | The Regents of the University of California | ALPHA-2-BETA-1 INTEGRIN INHIBITORS AND METHODS OF USE THEREOF |
| EP4294513A1 (en) | 2021-02-19 | 2023-12-27 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1993019088A1 (en) | 1992-03-17 | 1993-09-30 | Board Of Regents, The University Of Texas System | Neurotrophic peptides |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| WO1999058139A2 (en) * | 1998-05-08 | 1999-11-18 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| DE60127656T2 (de) * | 2000-02-25 | 2007-12-20 | Immunex Corp., Seattle | Integrin antagonisten |
| US20040121031A1 (en) | 2002-12-09 | 2004-06-24 | Muhammed Majeed | Novel topical skin care and nutraceutical applications of Glabridin or extracts containing a defined amount (4-90%) of Glabridin |
| US7101707B2 (en) | 2002-12-23 | 2006-09-05 | Cedars-Sinai Medical Center | Secondary sprouting for isolation and expansion of endothelial sprout cells and endothelial precursor cells from a mixed population and for screening substances |
| CN1933851B (zh) * | 2004-03-24 | 2011-09-14 | 艾伯特生物治疗学公司 | 使用抗-α5β1抗体抑制癌细胞增殖 |
| JP4857259B2 (ja) | 2004-03-24 | 2012-01-18 | アボット バイオセラピューティクス コーポレイション | 癌細胞増殖を阻害するための抗α５β１抗体の使用 |
| CA2611319A1 (en) * | 2005-06-07 | 2006-12-14 | William F. Degrado | Inhibitors of the .alpha.2.beta.1/gpia-iia integrin |
| EP1984391A4 (en) | 2006-01-19 | 2009-08-12 | Eyegene Inc | PEPTIDE-SUBSTANCED PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF DISEASES CONNECTED WITH THE VASCULAR SYSTEM |
| EP1998759A2 (en) | 2006-03-23 | 2008-12-10 | Schering Corporation | Combinations of hcv protease inhibitor(s) and cyp3a4 inhibitor(s), and methods of treatment related thereto |
| EP2029156A4 (en) * | 2006-05-01 | 2010-07-21 | Univ Southern California | COMBINATION THERAPY FOR CANCER TREATMENT |
| US20080267978A1 (en) | 2006-08-28 | 2008-10-30 | Mary Zutter | Anti-angiogenic targets for cancer therapy |
| WO2009114776A2 (en) | 2008-03-14 | 2009-09-17 | Visen Medical, Inc. | Integrin targeting agents and methods of using same |
| US20100105644A1 (en) | 2008-10-27 | 2010-04-29 | The Regents Of The University Of Michigan | Botanical composition for enhanced skin repair and uses thereof |
| WO2010070675A2 (en) | 2008-12-01 | 2010-06-24 | Laila Pharmaceuticals Pvt. Ltd | Topical formulation(s) for the treatment of inflammation, skin and mucosal disorders and other diseases thereof |
| WO2011146842A1 (en) | 2010-05-20 | 2011-11-24 | Temple University - Of The Commonwealth System Of Higher Education | Process for synthesis of silane dipeptide analogs |
| US20110311335A1 (en) * | 2010-06-21 | 2011-12-22 | Douglas Wike | Removable fastener |
| US20110319335A1 (en) | 2010-06-23 | 2011-12-29 | Xiaodong Feng | Combined administration of integrin receptor antagonists for anti-angiogenic therapy |
| IL210587A0 (en) | 2011-01-12 | 2011-03-31 | Adel Jamil Hidmi | Natural preparation for treatment of skin sores and lesions |
| US8946159B2 (en) * | 2011-12-22 | 2015-02-03 | California Northstate College Of Pharmacy, Llc | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
-
2011
- 2011-12-22 US US13/374,369 patent/US8946159B2/en active Active
-
2012
- 2012-11-07 US US13/671,462 patent/US8815805B2/en active Active
- 2012-12-18 EP EP12859266.4A patent/EP2793924B1/en active Active
- 2012-12-18 EP EP20194742.1A patent/EP3777877B1/en active Active
- 2012-12-18 JP JP2014549212A patent/JP6224615B2/ja active Active
- 2012-12-18 WO PCT/US2012/070399 patent/WO2013096335A1/en not_active Ceased
- 2012-12-18 CN CN201280070464.9A patent/CN104159596B/zh active Active
-
2014
- 2014-12-18 US US14/575,266 patent/US10722555B2/en active Active
-
2020
- 2020-06-12 US US16/899,859 patent/US11318184B2/en active Active
-
2022
- 2022-03-25 US US17/704,522 patent/US12053504B2/en active Active
-
2024
- 2024-06-24 US US18/752,340 patent/US20240342240A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ706836A (en) | Methods of treating cancer | |
| JP2015506352A5 (enExample) | ||
| JP2014502638A5 (enExample) | ||
| JP2017505782A5 (enExample) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| JP2015536964A5 (enExample) | ||
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| JP2012255026A5 (enExample) | ||
| JP2010209081A5 (enExample) | ||
| TN2012000335A1 (en) | Antibody formulation and therapeutic regimens | |
| PL3489261T3 (pl) | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu | |
| JP2016533366A5 (enExample) | ||
| PL3791896T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| JP2015500225A5 (enExample) | ||
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| JP2016528162A5 (enExample) | ||
| PH12016502354A1 (en) | Pharmaceutical composition | |
| JP2016520528A5 (enExample) | ||
| JP2017519027A5 (enExample) | ||
| MX2018012457A (es) | Terapia combinatoria con inhibidores notch y cdk4/6. | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| EP2682459A4 (en) | ONCOLYTIC ADENOVIRES FOR A TEMPORARY THERAPY AND USE THEREOF | |
| JP2014523398A5 (enExample) | ||
| IL231757A (en) | Antagonists ras for the treatment of malignant and non-malignant diseases | |
| JP2015527374A5 (enExample) |